Position in LLY
as of Jun 30, 2026
· filed Jul 2, 2026
Position Value
$82,760
+$19,296 QoQ
Shares Held
69
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#4,497
of 4,604 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cedar Mountain Advisors, LLC holds $655,207 across 12 Drug Manufacturers - General names. LLY ranks #4 (12.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
630 | $158,533 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,215 | $156,127 | |
| 3 | JNJ |
Johnson & Johnson
|
482 | $122,413 | |
| 4 | LLY |
ELI LILLY & Co
This page
|
69 | $82,760 | |
| 5 | PFE |
Pfizer Inc
|
1,691 | $40,719 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
271 | $34,238 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
363 | $20,916 | |
| 8 | NVS |
Novartis AG
|
105 | $16,455 |
All Filings in LLY
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,760 | 69 | Shares | Sole | 2026-07-02 | |
| 2026-03-31 | $63,464 | 69 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $66,630 | 62 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $47,306 | 62 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $7,795 | 10 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $21,473 | 26 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $20,072 | 26 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $40,753 | 46 | Shares | Sole | 2024-10-15 | |
| 2024-06-30 | $27,161 | 30 | Shares | Sole | 2024-07-11 | |
| 2024-03-31 | $25,672 | 33 | Shares | Sole | 2024-04-16 | |
| 2023-12-31 | $19,236 | 33 | Shares | Sole | 2024-01-16 | |
| 2023-09-30 | $16,113 | 30 | Shares | Sole | 2023-10-23 | |
| No filing history on record for this holder in this stock. | ||||||